It was in this setting that inhibitors of the proximal complement cascade were viewed as a promising next generation of complement inhibitor therapy for PNH [3], both as a potentially more effective treatment for newly diagnosed patients and also as a novel option for patients with a suboptimal response to C5 inhibition. Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.